Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference
Rhea-AI Summary
Tivic Health (NASDAQ:TIVC) announced that CEO Jennifer Ernst will present a corporate update at the Emerging Growth Virtual Conference on January 22, 2026 at 4:10–4:20 PM ET. The presentation will cover recent milestones in advancement of Entolimod, including scale-up validation for manufacturing and the vertical integration of Velocity Bioworks, a San Antonio contract development and manufacturing organization.
The company said the Velocity Bioworks addition provides in‑house manufacturing capability and potential new revenue streams, and is expected to reduce production costs, eliminate outsourcing delays, and accelerate cGMP validation for Entolimod. A live webcast and archived replay will be available.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TIVC gained 0.79%, reflecting a mild positive market reaction. Argus tracked a peak move of +18.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $24K to the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TIVC was down 0.81% while peers like VERO (-11.53%), NUWE (-5.18%) and others also declined, but momentum scanners showed no coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Manufacturing scale-up | Positive | +2.2% | Announced 200x Entolimod manufacturing scale-up with validated 50-liter batch. |
| Jan 08 | Acquisition webcast | Positive | +6.0% | Webcast to discuss CDMO asset acquisition and strategic CDMO revenue potential. |
| Dec 11 | CDMO acquisition | Positive | +11.8% | Acquired cGMP assets, launched Velocity Bioworks and secured $90M+ financing package. |
| Nov 18 | BARDA meeting | Positive | +25.1% | Secured BARDA TechWatch meeting to present Entolimod ARS data and BLA plans. |
| Nov 14 | Earnings update | Negative | -8.2% | Q3 2025 results showed low revenue, operating losses and cash constraints. |
Positive development and financing news has typically aligned with upside moves, while earnings drove a negative reaction.
Over the past few months, Tivic has shifted toward its Entolimod program and in‑house CDMO model. On Nov 18, 2025, securing a BARDA TechWatch meeting for Entolimod aligned with a 25.08% gain. The Dec 11, 2025 Scorpius CDMO asset acquisition and related $90M+ financing support further manufacturing control and drew a double‑digit rise. January 2026 updates on Velocity Bioworks and Entolimod scale‑up also saw positive reactions, while Q3 2025-11-14 earnings, highlighting continued losses, coincided with an -8.17% decline.
Regulatory & Risk Context
An effective S-3 resale registration dated Oct 17, 2025 covers up to 1,580,437 shares of common stock for selling stockholders. Tivic does not receive proceeds from resales and only gets cash if warrants are exercised. Multiple 424B3 supplements, including on Jan 20, 2026, indicate active usage of this resale capacity.
Market Pulse Summary
This announcement highlights Tivic’s plan to showcase recent Entolimod manufacturing milestones and the integration of Velocity Bioworks at an investor conference on January 21–22, 2026. It reinforces messaging from recent SEC filings about in‑house cGMP capabilities and potential CDMO revenue streams. Investors may watch for any new data points versus the January 2026 investor deck, along with how these operational updates intersect with previously disclosed resale registrations and financing structures.
Key Terms
immunotherapeutics medical
current Good Manufacturing Practice (cGMP) regulatory
vertical integration technical
manufacturing readiness technical
AI-generated analysis. Not financial advice.
Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™
FREMONT, CA / ACCESS Newswire / January 20, 2026 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics company, today announced that its CEO will provide a corporate update focused on recent developments in its advancement of Entolimod ™ during the Emerging Growth Virtual Conference on January 21 and 22, 2026
WHO: Jennifer Ernst, Chief Executive Officer
WHERE: January 22, 2026
WHEN: 4:10 - 4:20 Eastern Time
During the virtual conference update, Ms. Ernst will highlight recent company developments, including scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks-a San Antonio-based contract development and manufacturing organization which provides the company with in-house manufacturing capability and new potential revenue streams. This strategic addition is expected to reduce production costs, eliminate outsourcing delays, and accelerate validation of current Good Manufacturing Practice (cGMP) for Entolimod, demonstrated in recent scale-up.
Attendees are encouraged to attend and/or listen to the presentation. Please register for the event at the below link.
https://goto.webcasts.com/starthere.jsp?ei=1717095&tp_key=3c898db1bd&sti=tivc
If attendees cannot join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com.
About the Emerging Growth
The Emerging Growth Virtual Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Entolimod
Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that triggers NF-kappaB pathway signaling, activating anti-apoptotic and cell protective mechanisms. Entolimod for Acute Radiation Syndrome (ARS) has been the subject of extensive trials under the FDA's Animal Rule and in animal models has demonstrated robust survival rates, enhanced gastrointestinal tract recovery, and improved hematopoiesis. To see the complete Tivic pipeline visit: https://tivichealth.com/pipeline/
About Tivic
Tivic is a late-stage immunotherapeutics company whose lead drug candidate, Entolimod to treat ARS, is in late-stage development. Entolimod is a TLR5 agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The pipeline includes Entolimod to treat Neutropenia, and lymphocyte exhaustion, as well as Entolasta™, an immunologically optimized variant of Entolimod for chronic applications.
Tivic's wholly owned subsidiary, Velocity Bioworks, is a full-service CDMO based in San Antonio, Texas. Tivic also leverages Velocity Bioworks' manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes and supply chain security. To learn more about Tivic, visit: https://tivichealth.com/
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim, "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the ability of the company to achieve the expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all; changes to the company's relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in the future; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Media Contact:
DJ Freyman
DJ@fastrackPR.com
SOURCE: Tivic Health Systems
View the original press release on ACCESS Newswire
FAQ
When will Tivic Health (TIVC) CEO present at the Emerging Growth Virtual Conference?
What topics will Tivic Health (TIVC) cover in the January 22, 2026 presentation?
How does Velocity Bioworks affect Tivic Health's (TIVC) manufacturing plans?
Will Tivic Health (TIVC) make the webcast of the presentation available after the event?
How long is Tivic Health's (TIVC) CEO presentation at the conference?
Where can investors register to watch Tivic Health (TIVC) at the Emerging Growth Virtual Conference?
